Print
Email
Bruker BioSciences Corp. (BRKR) filed Quarterly Report for the period ended 2011-09-30.
Bruker Corp. has a market cap of $2.29 billion; its shares were traded at around $13.79 with a P/E ratio of 17.4 and P/S ratio of 1.7. Bruker Corp. had an annual average earning growth of 45.9% over the past 5 years.
This is the annual revenues and earnings per share of BRKR over the last 10 years. For detailed 10-year financial data and charts, go to 10-Year Financials of BRKR.
Highlight of Business Operations:
For the three months ended September 30, 2011, our revenue increased by $108.2 million, or 34.9%, to $418.4 million, compared to $310.2 million for the comparable period in 2010. Included in this change in revenue is an increase of approximately $28.7 million from the impact of foreign exchange due to the weakening of the U.S. Dollar versus the Euro, Swiss Franc and other foreign currencies and an increase of approximately $45.7 million attributable to acquisitions completed over the last twelve months. Excluding the effects of foreign exchange and our recent acquisitions, revenue increased by $33.8 million, or 10.9%. The increase in revenue on an adjusted basis is attributable to both the Scientific Instruments segment, which increased by $31.6 million, or 10.9%, and the Energy & Supercon Technologies segment, which increased by $2.9 million, or 12.9%.For the nine months ended September 30, 2011, our revenue increased by $287.8 million, or 32.4%, to $1,176.6 million, compared to $888.8 million for the comparable period in 2010. Included in this change in revenue is an increase of approximately $72.0 million from the impact of foreign exchange due to the weakening of the U.S. Dollar versus the Euro, Swiss Franc and other foreign currencies and an increase of approximately $147.0 million attributable to acquisitions completed over the last twelve months. Excluding the effects of foreign exchange and our recent acquisitions, revenue increased by $68.8 million, or 7.7%. The increase in revenue on an adjusted basis is attributable to both the Scientific Instruments segment, which increased by $57.9 million, or 6.9%, and the Energy & Supercon Technologies segment, which increased by $13.3 million, or 21.7%.
Income from operations for the three months ended September 30, 2011 was $37.5 million, resulting in an operating margin of 9.0%, compared to income from operations of $39.3 million, resulting in an operating margin of 12.7%, for the comparable period in 2010. Income from operations for the nine months ended September 30, 2011 was $101.9 million, resulting in an operating margin of 8.7%, compared to income from operations of $104.1 million, resulting in an operating margin of 11.7%, for the comparable period in 2010. Included in income from operations are various charges to inventory, amortization of acquisition-related intangible assets and other acquisition-related costs, deferred offering costs that have been written-off and legal and other professional services fees related to our internal FCPA investigation totaling, in the aggregate, $12.6 million and $7.7 million in the third quarter of 2011 and 2010, respectively, and $34.3 million and $11.5 million for the first three quarters of 2011 and 2010, respectively. Excluding these charges, operating margins were 12.0% and 15.2% in the third quarter of 2011 and 2010, respectively, and 11.6% and 13.0% in the nine months ended September 30, 2011 and 2010, respectively. Operating margins decreased, despite growth in our revenues and gross profits, because of the mix of products sold and higher operating expenses.
For the three months ended September 30, 2011, our revenue increased by $108.2 million, or 34.9%, to $418.8 million, compared to $310.2 million for the comparable period in 2010. Included in this change in revenue is an increase of approximately $28.7 million from the impact of foreign exchange due to the weakening of the U.S. Dollar versus the Euro, Swiss Franc and other foreign currencies and an increase of approximately $45.7 million attributable to acquisitions completed over the last twelve months. Excluding the effects of foreign exchange and our recent acquisitions, revenue increased by $33.8 million, or 10.9%. The increase in revenue on an adjusted basis is attributable to both the Scientific Instruments segment, which increased by $31.6 million, or 10.9%, and the Energy & Supercon Technologies segment, which increased by $2.9 million, or 12.9%.
For the nine months ended September 30, 2011, our revenue increased by $287.8 million, or 32.4%, to $1,176.6 million compared to $888.8 million for the comparable period in 2010. Included in this change in revenue is an increase of approximately $72.0 million from the impact of foreign exchange due to the weakening of the U.S. Dollar versus the Euro, Swiss Franc and other foreign currencies and an increase of approximately $147.0 million attributable to acquisitions completed over the last twelve months. Excluding the effects of foreign exchange and our recent acquisitions, revenue increased by $68.8 million, or 7.7%. The increase in revenue on an adjusted basis is attributable to both the Scientific Instruments segment, which increased by $57.9 million, or 6.9%, and the Energy & Supercon Technologies segment, which increased by $13.3 million, or 21.7%.
Subscribe RSS
